Multiple drug resistance (MDR) and metastasis are two major factors that contribute to the failure of cancer treatment. However, the relationship between MDR and metastasis has not been characterized. Additionally, the role of the E3 ubiquitin ligase Cbl-b in metastasis of MDR gastric and breast cancer is not well known. In the present study, we found that MDR gastric and breast cancer cells possess a typical mesenchymal phenotype and enhanced cell migration capacity. Additionally, Cbl-b is poorly expressed in MDR gastric and breast cancer cells. In MDR gastric adenocarcinoma tissues, gastric cancer patients with low Cbl-b expression were more likely to have tumor invasion (P = .016) and lymph node metastasis (P = .007). Moreover, overexpression of Cbl-b reduced cell migration in MDR cell cultures both in vitro and in vivo. Cbl-b overexpression also prevented EMT by inducing ubiquitination and degradation of EGFR, leading to inhibition of the EGFR-ERK/Akt-miR-200c-ZEB1 axis. However, further overexpression of EGFR on a background of Cbl-b overexpression restored both the mesenchymal phenotype and cell migration capacity of MDR gastric and breast cancer cells. These results suggest that Cbl-b is an important factor for maintenance of the epithelial phenotype and inhibition of cell migration in MDR gastric and breast cancer cells.
Introduction
Multiple drug resistance (MDR) and metastasis are two major factors that contribute to the failure of cancer treatment [1, 2] . However, there is no conclusive evidence demonstrating an association between MDR and tumor metastasis or that MDR and metastasis regulate each other.
Previous studies have shown that MDR breast cancer cells are more metastatic than their parental cells, possibly because of the loss of E-cadherin expression [3] . The E-cadherin transcription repressors slug, twist, and ZEB1/2 are overexpressed in MDR breast cancer cells [4] . In cancer cells, the loss of E-cadherin results in epithelial-mesenchymal transition (EMT) and contributes to increased invasion and metastasis [5, 6] . Another important characteristic of tumor cells is their ability to express growth factor receptors, such as epidermal growth factor receptor (EGFR), which contribute to tumor progression, invasion, and metastasis [7] . EGFR signaling can mediate EMT in hepatocellular carcinoma [8] . Moreover, betacellulin can induce ovarian cancer cell migration via slug-dependent downregulation of E-cadherin via the EGFR signaling pathway [9] . However, whether the enhanced tumor metastasis observed in MDR gastric and breast cancer cells results from EGFR signaling pathway-regulated EMT remains unclear.
Because the activation of receptor tyrosine kinases can lead to tumor invasion and metastasis [10] , activation of the receptor tyrosine kinase degradation system has become a new strategy for the inhibition of tumor metastasis. One recent study has shown that Casitas B-lineage lymphoma (Cbl) family members downregulated EGFR expression via their E3 ubiquitin ligase activity [11] . Another study showed that c-Cbl-mediated ubiquitination and downregulation of EGFR promoted tumor growth in colorectal cancer cells [12] . Our previous studies demonstrated that Cbl-b reversed drug resistance by both preventing the transporter functions of P-glycoprotein (P-gp) by inhibiting its translocation into caveolae and inhibiting EGFR downstream PI3K/ Akt signaling [13, 14] . Another recent study from our laboratory showed that Cbl-b could repress IGF-1-mediated EMT through microRNA-200c-regulated ZEB2 in gastric cancer cells [15] . However, these studies did not determine whether Cbl-b could regulate the invasion and metastasis of MDR cancer cells. Because Cbl-b is expressed at low levels in MDR gastric cancer cells [14] , we investigated whether this low expression of Cbl-b relieved inhibition of the EGFR pathway and thereby promoted EMT and tumor metastasis.
In our study, we demonstrate that Cbl-b maintains an epithelial phenotype by promoting ubiquitination and degradation of EGFR, thereby preventing the EGFR-ERK/Akt-miR-200c-ZEB1 axis and preventing tumor invasion and metastasis in MDR gastric and breast cancer cells.
Materials and Methods

Patients and Tissue Samples
Two hundred eight-two surgically resected gastric cancer cases were examined at the Department of Pathology, The First Hospital of China Medical University, between 1 January 2005 and 31 December 2005. No patient had received preoperative chemotherapy or radiotherapy. Age, sex, differentiation, depth of invasion, lymph node metastasis, and tumor node metastasis (TNM) stage were evaluated by reviewing medical charts and pathology records. This study was approved by the Human Ethics Review Committee of the First Hospital of China Medical University. Written informed consents were obtained from participants in accordance with the Declaration of Helsinki and its later revision. Tissue array methods and immunohistochemical staining were performed as previously described [13, 14] .
Immunohistochemistry
Immunohistochemical staining for Cbl-b and P-gp was performed using a streptavidin-peroxidase procedure as described previously [13] . Antibodies against Cbl-b and P-gp were from Santa Cruz Biotechnology (Santa Cruz, CA). Immunostaining was considered positive when the tumor mass occupied more than 10% of the cross-sectional core area and when 10% or more of the neoplastic cells were stained.
Cell Culture
Gastric cancer SGC7901 cells and breast cancer MCF-7 cells were purchased from the Academy of Military Medical Science (Beijing, China).
The adriamycin-resistant variant of SGC7901 (SGC7901/Adr) was kindly provided by the Fourth Military Medical University (Xi'an, China). The adriamycin-resistant variant of MCF-7 (MCF-7/Adr) was established by selecting for resistant colonies by culturing the parent cell line in 0.2 μg/ml of adriamycin. The drug-containing medium was changed weekly, and colonies that had propagated from single cells were selected. Clonal cell lines expanded from such a colony were subsequently selected in 1 μg/ml of adriamycin.
Transfections of Cbl-b WT and EGFR WT Plasmid
Transfections of Cbl-b WT and EGFR WT plasmid were performed as described previously [13, 14] . SGC7901/Adr and MCF-7/Adr cells were seeded at 4 × 10 5 cells/well in six-well plates overnight and then transfected by Lipofectamine 2000 reagent with pcDNA 3.1 plasmid including full-length Cbl-b or EGFR. pcDNA 3.1 vector served as the negative control. After transfections for 48 hours, the expression of Cbl-b and EGFR was evaluated by Western blot. 
Western Blot and Immunoprecipitation
Western blot and immunoprecipitation were performed as described previously [15] [16] [17] . For immunoprecipitation, cell lysates were mixed with the indicated primary antibody and protein A-sepharose beads at 4°C overnight. The immunoprecipitated proteins were eluted by heat treatment at 100°C with 2× sampling buffer. Total cell proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis. The membranes were blocked with 5% skimmed milk in Tris-buffered saline Tween-20 buffer overnight. Various primary antibodies were as follows: Cbl-b, P-gp, p-ERK, ERK (Santa Cruz, USA); ZEB1, ZEB2, snail, slug, twist1, twist2 (Abcam, England); p-EGFR, EGFR, E-cadherin, Vimentin, p-Akt, Akt, (Cell Signaling Technology, USA). Then, the membrane was incubated with the secondary antibodies for 30 minutes at room temperature. Finally, proteins on the membranes were visualized by an enhanced chemiluminescence reagent in the electrophoresis gel imaging analysis system. at room temperature in the dark. After mounting with the Slow Fade Antifade Kit, the cells were visualized by fluorescence microscopy (Olympus, Japan).
Transwell Migration
Migration assay was performed using Boyden chambers and polycarbonate inserts with 8-μm pore size membranes. The cells were seeded at 1 × 10 4 cells/well. After incubation for 24 hours, nonmigrated cells were removed from the upper surface of the chamber. The migrated cells on the lower surface of the chamber were stained using the Wright-Giemsa method. The migrated cells were counted under bright-field microscope.
Wound Healing Assay
SGC7901/Adr and MCF-7/Adr cells were seeded at 4 × 10 5 cells/ well in six-well plates overnight. Then, the cells were transfected with Cbl-b plasmid or empty vector for 48 hours. The cells grew to nearly 100% confluence in six-well plates. Then, the cell-free line was manually created by scratching the confluent cell monolayers using a 200-μl pipette tip. We randomly choose five scratched fields. The images were captured through bright-field microscope.
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
Referring to our previous method [15] , relative expression of microRNA was calculated via the comparative cycle threshold method, and the expression of U6 small nuclear RNA was used as reference. The forward primer for miR-200c was 5′-ACACTC-CAGCTGGGTAATACTG CCGGGTAA-3′. The PCR conditions were 10 minutes at 95°C followed by 45 cycles at 95°C for 15 seconds and 58°C for 34 seconds.
Tumor Metastasis In Vivo
Female BALB/c nude mice, 4 to 6 weeks of age, were from the National Laboratory Animal Center (Shanghai, China 
Statistical Analysis
All the presented data were expressed as the mean ± SD, and representative results were from three independent experiments. Statistical analysis was carried out using SPSS 18.0 software. Statistical comparisons were calculated by Student's two-tailed t test. P b .05 was considered statistically significant.
Results
Cell Migration Is Enhanced in MDR Gastric and Breast Cancer Cells with a Mesenchymal Phenotype
We first examined cell migration in MDR and parental gastric cancer and breast cancer cells. Our results showed that cell migration was increased in MDR gastric cancer SGC7901/Adr and breast cancer MCF-7/Adr cells compared with their parental SGC7901 and MCF-7 cells ( Figure 1A) . Moreover, SGC7901 and MCF-7 cells exhibited typical epithelial phenotypes with tight junctions, whereas SGC7901/Adr and MCF-7/Adr cells adopted an elongated and spindle-shaped mesenchymal phenotype ( Figure 1B) . Consistent with the mesenchymal phenotype, both SGC7901/Adr and MCF-7/Adr cells expressed high levels of the mesenchymal marker Vimentin and low levels of the epithelial marker E-cadherin ( Figure 1C ). Cbl-b was also expressed at low levels in SGC7901/Adr and MCF-7/Adr cells compared with parental cells ( Figure 1C ). These results suggest that enhanced migration of MDR gastric and breast cancer cells likely results from EMT and that Cbl-b may regulate cell migration.
Cbl-b Expression Negatively Correlates with Tumor Invasion and Metastasis in MDR Gastric Cancer Patients
The emergence of P-gp mediated MDR [14] . Immunohistochemical analysis of 282 gastric adenocarcinoma tissues revealed P-gp expression in 37.6% (106/282) and Cbl-b expression in 63.1% (178/ 282). Representative pictures for positive and negative P-gp or Cbl-b expression were shown in Figure 2A . In P-gp-negative gastric adenocarcinoma tissues, Cbl-b had no significant influence on TNM (P N .05) and lymph node metastasis (P N .05) of gastric cancer patients. However, in P-gp-positive gastric adenocarcinoma tissues, gastric cancer patients expressing Cbl-b were in T1 and T2 invasion (P = .016), exhibit no lymph node metastasis (P = .007), and early-stage TNM (P = .008) ( Table 1 ). These data indicate that Cbl-b expression negatively correlates with tumor invasion and metastasis in MDR gastric cancer patients.
Overexpression of Cbl-b Inhibits MDR Cancer Cell Migration In Vitro and In Vivo
We further investigated Cbl-b-mediated inhibition of MDR cancer cell migration using wound healing assays. We transiently transfected SGC7901/Adr and MCF-7/Adr cells with Cbl-b wild-type (WT) plasmid and found that wound gaps were significantly larger in Cbl-b Figure 2B ). Furthermore, overexpression of Cbl-b inhibited the cell migration ability of both MDR cancer cell lines ( Figure 2C ). However, we did not observe any difference in cell viability at 24 hours between the cells transfected with control plasmid and Cbl-b WT (100% vs. 93.67 ± 4.50% for SGC7901/Adr, 100% vs. 94.33 ± 3.92% for MCF-7/Adr, respectively; P N .05). We next examined whether Cbl-b could inhibit tumor metastasis in vivo. We injected SGC7901/Adr cells with or without ectopic expression of Cbl-b into the tail vein of mice and then sacrificed the animals 21 days later for lung tissue examination. Results from [ 18 F] FDG micro-PET assays revealed that mice injected with Cbl-b WT cells had significantly reduced metastatic lung tissue compared with the control (Figure 2D ). Consistent with these findings, H&E staining showed significantly decreased numbers of metastatic tumor colonies in the lungs of nude mice injected with Cbl-b WT-transfected cells compared with those injected with control cells ( Figure 2E ). These data suggest that Cbl-b impaired cell migration in MDR gastric and breast cancer cells.
WT-transfected SGC7901/Adr and MCF-7/Adr cells compared with control cells transfected with empty vector plasmid (
Overexpression of Cbl-b Reversed the Mesenchymal Phenotype of MDR Gastric and Breast Cancer Cells
We further investigated whether Cbl-b-mediated inhibition of cell migration was associated with EMT by transfecting SGC7901/Adr and MCF-7/Adr cells with Cbl-b WT or control plasmids. Cbl-b WT-transfected cells adopted a typical epithelial-like morphology with tight junctions ( Figure 3A) . The increase of E-cadherin and the decrease of Vimentin in Cbl-b WT-transfected cells were detected by immunofluorescence ( Figure 3B ) and Western blotting ( Figure 3C ). Downregulation of transcription factor ZEB1 was also detected in Cbl-b WT-transfected cells ( Figure 3C ). Our data indicate that Cbl-b maintains the epithelial phenotype in MDR gastric and breast cancer cells. E-cadherin were also detected in co-transfected cells ( Figure 6A) . Moreover, the increase in miR-200c levels was partially reversed in EGFR WT and Cbl-b WT co-transfected cells compared with cells transfected with Cbl-b WT alone ( Figure 6B) . Finally, the simultaneous overexpression of both EGFR and Cbl-b partially recovered the cell migration capacity ( Figure 6C ). These results suggest that Cbl-b reversed the mesenchymal phenotype and prevented cell migration by inhibition of the EGFR-ERK/ Akt-miR-200c-ZEB1 axis.
Overexpression of Cbl-b Represses the Mesenchymal Phenotype by Inducing Ubiquitination and Degradation of EGFR and Inhibiting the ERK/Akt-miR-200c-ZEB1 Axis
Discussion
Drug-induced MDR1 expression enables cancer cells to become resistant to multiple drugs, leading to the failure of antitumor treatment. Recent studies have shown that the MDR-positive phenotype correlates with a more aggressive mesenchymal phenotype and poor prognosis [19, 20] . Our current study identifies an enhanced capacity for cell migration in MDR gastric cancer and breast cancer cells compared with their parental cells. These MDR cancer cells also exhibit a typical mesenchymal phenotype accompanied by low Cbl-b expression. Interestingly, previous studies from our laboratory showed that Cbl-b could reverse drug resistance in MDR cancer cells [13, 14] . Additionally, Cbl-b improves the prognosis of RANK-positive breast cancer through the inhibition of cell migration and metastasis induced by RANKL [21] . However, whether Cbl-b regulates tumor invasion and metastasis in MDR gastric and breast cancer cells is unknown until now. Our present clinical data suggest that MDR gastric cancer patients with low levels of Cbl-b expression are more likely to have tumor invasion and lymph node metastasis. Consistent with these findings, we demonstrated that overexpression of Cbl-b prevented cell migration of MDR gastric and breast cancer cells both in vitro and in vivo. Our results indicate that Cbl-b is an important inhibitor of tumor invasion and metastasis in MDR gastric and breast cancer cells.
We next investigated the mechanism by which Cbl-b regulates tumor invasion and metastasis in MDR gastric and breast cancer cells. Emerging evidence suggests that EMT is a vital event in tumor invasion and metastasis [22, 23] . Previous studies including our own have shown that the transcription factors ZEB1/2 can down-regulate the expression of E-cadherin and promote EMT, whereas the miR-200 family can inhibit ZEB1/2 expression [15, 24, 25] . Furthermore, overexpression of EGFR increases levels of ZEB1/2 and promotes TGF-β-induced EMT [26] . Notably, the Cbl family proteins serve as negative regulators of many receptor tyrosine kinases such as EGFR. In breast cancer cells, ERβ1 inhibits EMT by enhancing the EGFR-c-Cbl interaction, thereby inducing EGFR degradation [27] . Another study showed that miR-675 binding to c-Cbl and Cbl-b mRNA increased the stability of EGFR and enhanced cell migration [28] . Moreover, ionizing radiation-inducible miR-30e promoted glioma cell invasion through EGFR stabilization by targeting Cbl-b [29] . However, whether Cbl-b regulates tumor invasion and metastasis by targeting EGFR in MDR gastric and breast cancer cells has not been previously reported. We have shown that overexpression of Cbl-b promotes an interaction between Cbl-b and EGFR, leading to the ubiquitination and degradation of EGFR. Moreover, Cbl-b overexpression inhibits the EGFR-ERK/ Akt-miR-200c-ZEB1 axis and further represses the mesenchymal phenotype. However, further overexpression of EGFR on a background of Cbl-b overexpression can relieve Cbl-b-mediated EGFR degradation and restore EGFR expression, mesenchymal phenotype, and cell migration capacity in MDR gastric and breast cancer cells. Therefore, EGFR is a key target of Cbl-b in the regulation of tumor invasion and metastasis in MDR gastric and breast cancer cells.
In summary, our study demonstrates that Cbl-b maintains the epithelial phenotype and prevents cell migration by inhibition of the EGFR-ERK/Akt-miR-200c-ZEB1 axis in MDR gastric and breast cancer cells (Figure 7 ). Cbl-b may also be a potential prognostic indicator for the invasion and metastasis of MDR cancers.
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